Expedition Therapeutics
Expedition Therapeutics develops treatments for inflammatory and respiratory diseases, led by an oral, once-daily DPP1 inhibitor for COPD.
- Company
- San Francisco, CA, USUnited States
Expedition Therapeutics develops treatments for inflammatory and respiratory diseases, led by an oral, once-daily DPP1 inhibitor for COPD.
expeditiontx.comCrawled Oct 25, 2026
General Atlantic led financing for Expedition Therapeutics, with participation from RA Capital and Vivo Capital. The company dosed its first patient in a Phase 2 COPD trial for EXPD-101, with Brett Zbar joining the board.
Expedition Therapeutics secured funding to advance EXPD-101, a Phase 2-ready oral DPP1 inhibitor, into global development for COPD and neutrophil-driven diseases. Sofinnova Investments and Novo Holdings co-led the financing.
Brett Zbar, MD, oversees General Atlantic’s Life Sciences sector as a Managing Director. Before joining in 2020, he held roles at Foresite Capital and Aisling Capital, focusing on healthcare investments.
Gabrielle Poirier leads clinical operations at Expedition Therapeutics, with over 25 years of experience in global clinical development across therapeutic areas. She previously managed a pre-eclampsia program at Comanche BioPharma.
Gorjan Hrustanovic, PhD, is a Partner at BVF Partners, overseeing biotech investments for private and public companies. He serves on the boards of Olema Pharmaceuticals, Kymera Therapeutics, Forward Therapeutics, and Plexium.
Ralph trained in internal medicine, pulmonary, and critical care medicine at Yale after attending Rush Medical College. He later worked in industry roles at Bayer, Pfizer, Immunex, and Amgen, focusing on asthma.
Expedition Therapeutics develops treatments for inflammatory and respiratory diseases, aiming to transform COPD care by addressing fundamental disease mechanisms.
Expedition Therapeutics secures $115 million in Series B funding to support development of its DPP1 inhibitor EXPD-101. The drug enters a global Phase 2 clinical trial targeting chronic obstructive pulmonary disease (COPD). The financing is oversubscribed, accelerating the company’s pipeline advancement.
Aug 2026Pulse 2.0News article
Expedition Therapeutics secures $115 million in funding to progress EXPD-101, an oral DPP1 inhibitor, into Phase 2 trials for chronic obstructive pulmonary disease (COPD). The company has already dosed the first patient in the study. This investment supports further clinical development of the experimental treatment.
Aug 2026Pharmacally -News article
Expedition Therapeutics secures an oversubscribed **$115 million Series B** led by General Atlantic, with RA Capital and Vivo Capital joining existing investors. The company advances its **next-generation DPP1 inhibitor (EXPD-101)** for COPD, having dosed the first patient in its **Phase 2 clinical trial**. Brett Zbar, M.D., joins the board as Global Head of Life Sciences at General Atlantic.
Aug 2026Expedition Therapeutics -News article
Expedition Therapeutics secures funding to advance research and development for chronic obstructive pulmonary disease (COPD) treatments. The investment reflects growing investor interest in novel biotech approaches targeting respiratory diseases. The company’s focus highlights emerging scientific efforts to translate new biology into clinical applications.
Oct 2025ExcedrNews article